Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index

Mesut Savas; Taulant Muka; Vincent L. Wester; Erica L. T. van den Akker; Jenny A. Visser; Gert-Jan Braunstahl; Sandra N. Slagter; Bruce H. R. Wolffenbuttel; Oscar H. Franco; Elisabeth F. C. van Rossum

doi:10.1210/jc.2017-01133

Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index

Mesut Savas, Taulant Muka, Vincent L. Wester, Erica L. T. van den Akker, Jenny A. Visser, Gert-Jan Braunstahl, Sandra N. Slagter, Bruce H. R. Wolffenbuttel, Oscar H. Franco, Elisabeth F. C. van Rossum^*

^*Corresponding author for this work

Center for Liver, Digestive and Metabolic Diseases (CLDM)

Research output: Contribution to journal › Article › Academic › peer-review

32 Citations (Scopus)

49 Downloads (Pure)

Abstract

Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear.

Objective: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits.

Design: Cross-sectional cohort study.

Setting: General population from the northern Netherlands.

Participants: A total of 140,879 adult participants in the population-based Lifelines Cohort Study.

Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors.

Results: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI.

Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.

Original language	English
Pages (from-to)	3765-3774
Number of pages	10
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	102
Issue number	10
DOIs	https://doi.org/10.1210/jc.2017-01133
Publication status	Published - 1-Oct-2017

Keywords

BONE-MINERAL DENSITY
FUROATE NASAL SPRAY
INHALED CORTICOSTEROIDS
FLUTICASONE PROPIONATE
RISK-FACTORS
TRIAMCINOLONE ACETONIDE
INDUCED LIPODYSTROPHY
ORAL CORTICOSTEROIDS
ASTHMATIC-PATIENTS
ADVERSE EVENTS

Access to Document

10.1210/jc.2017-01133

Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass IndexFinal publisher's version, 524 KBLicence: Taverne

Handle.net

Persistent link

Lifelines Biobank
Bakker, S. (Creator), Dotinga, A. (Creator), Vonk, J. M. (Creator), Smidt, N. (Creator), Scholtens, S. (Creator), Swertz, M. (Creator), Wijmenga, C. (Creator), Wolffenbutel, B. H. (Creator), Stolk, R. (Creator), van Zon, S. (Creator), Rosmalen, J. (Creator), Postma, D. S. (Creator), de Boer, R. (Creator), Navis, G. (Creator), Slaets, J. (Creator), Ormel, J. (Creator), van Dijk, F. (Creator) & Bolmer, B. (Data Manager), Lifelines, 2006
https://www.lifelines.nl/ and one more link, https://catalogue.lifelines.nl/ (show fewer)
Dataset

Cite this

Savas, M., Muka, T., Wester, V. L., van den Akker, E. L. T., Visser, J. A., Braunstahl, G.-J., Slagter, S. N., Wolffenbuttel, B. H. R., Franco, O. H., & van Rossum, E. F. C. (2017). Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 102(10), 3765-3774. https://doi.org/10.1210/jc.2017-01133

@article{0f73c6a040b54ed6b3f05597a5142417,

title = "Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index",

abstract = "Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear.Objective: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits.Design: Cross-sectional cohort study.Setting: General population from the northern Netherlands.Participants: A total of 140,879 adult participants in the population-based Lifelines Cohort Study.Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors.Results: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI.Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.",

keywords = "BONE-MINERAL DENSITY, FUROATE NASAL SPRAY, INHALED CORTICOSTEROIDS, FLUTICASONE PROPIONATE, RISK-FACTORS, TRIAMCINOLONE ACETONIDE, INDUCED LIPODYSTROPHY, ORAL CORTICOSTEROIDS, ASTHMATIC-PATIENTS, ADVERSE EVENTS",

author = "Mesut Savas and Taulant Muka and Wester, {Vincent L.} and {van den Akker}, {Erica L. T.} and Visser, {Jenny A.} and Gert-Jan Braunstahl and Slagter, {Sandra N.} and Wolffenbuttel, {Bruce H. R.} and Franco, {Oscar H.} and {van Rossum}, {Elisabeth F. C.}",

year = "2017",

month = oct,

day = "1",

doi = "10.1210/jc.2017-01133",

language = "English",

volume = "102",

pages = "3765--3774",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "ENDOCRINE SOC",

number = "10",

}

Savas, M, Muka, T, Wester, VL, van den Akker, ELT, Visser, JA, Braunstahl, G-J, Slagter, SN , Wolffenbuttel, BHR, Franco, OH & van Rossum, EFC 2017, 'Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index', Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 10, pp. 3765-3774. https://doi.org/10.1210/jc.2017-01133

TY - JOUR

T1 - Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index

AU - Savas, Mesut

AU - Muka, Taulant

AU - Wester, Vincent L.

AU - van den Akker, Erica L. T.

AU - Visser, Jenny A.

AU - Braunstahl, Gert-Jan

AU - Slagter, Sandra N.

AU - Wolffenbuttel, Bruce H. R.

AU - Franco, Oscar H.

AU - van Rossum, Elisabeth F. C.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear.Objective: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits.Design: Cross-sectional cohort study.Setting: General population from the northern Netherlands.Participants: A total of 140,879 adult participants in the population-based Lifelines Cohort Study.Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors.Results: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI.Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.

AB - Context: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear.Objective: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits.Design: Cross-sectional cohort study.Setting: General population from the northern Netherlands.Participants: A total of 140,879 adult participants in the population-based Lifelines Cohort Study.Main Outcome Measures: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors.Results: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI.Conclusions: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.

KW - BONE-MINERAL DENSITY

KW - FUROATE NASAL SPRAY

KW - INHALED CORTICOSTEROIDS

KW - FLUTICASONE PROPIONATE

KW - RISK-FACTORS

KW - TRIAMCINOLONE ACETONIDE

KW - INDUCED LIPODYSTROPHY

KW - ORAL CORTICOSTEROIDS

KW - ASTHMATIC-PATIENTS

KW - ADVERSE EVENTS

U2 - 10.1210/jc.2017-01133

DO - 10.1210/jc.2017-01133

M3 - Article

SN - 0021-972X

VL - 102

SP - 3765

EP - 3774

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 10

ER -

Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Datasets

Lifelines Biobank

Cite this